Molecular Markers in Lung Cancer Pt 6: Dr. Glen Goss on Incorporating Markers Across a Health Care System (audio)
05/23/12 • 25 min
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
Dr. Glen Goss, University of Ottawa and NCI-Canada Lung Cancer Committee chair, discusses the potential and limitations of integrating molecular marker studies in advanced non-small cell lung cancer patients across a health care system.
Previous Episode
Molecular Markers in Lung Cancer Pt 5: Dr. David Spigel on Incorporating Targets into Clinical Trials (audio)
Dr. David Spigel, Sarah Cannon Cancer Center, discusses the benefits and challenges of conducting trials that include patient subgroups based on molecular markers.
Next Episode
Immunotherapies for Lung Cancer: MAGE-A3, Stimuvax, and Lucanix, by Dr. R. Govindan (audio)
Dr. Ramaswamy Govindan provides a summary of the science behind several promising immunotherapies for lung cancer and the clinical trials that could lead to them being integrated into our treatment plans.
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/gracecast-lung-cancer-audio-126564/molecular-markers-in-lung-cancer-pt-6-dr-glen-goss-on-incorporating-ma-6326776"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to molecular markers in lung cancer pt 6: dr. glen goss on incorporating markers across a health care system (audio) on goodpods" style="width: 225px" /> </a>
Copy